Several experimental models faithfully recapitulate many important facets of human metastatic disease. Here we have performed whole exome sequencing in five widely used experimental metastasis models that were independently derived through in vivo selection from heterogeneous human cancer cell lines. In addition to providing an important characterization of these model systems, our study examines the genetic evolution of metastatic phenotypes. We found that in vivo selected highly metastatic cell populations showed little genetic divergence from the corresponding parental population. However, selection of genetic variations that preexisted in parental populations, including the well-established oncogenic mutations
INTRODUCTION
An indispensable tool in the interrogation of the metastatic process has been the use of transplantable metastasis model systems in which cancer cells or tissues are engrafted into mouse hosts and phenotypically-stable metastatically-competent cancer cell populations are derived from in vivo selection. These transplantable metastasis models, derived from heterogenous human cancer cell lines (MDA_MB-231, H2030, PC9, 786-O, OS-RC-2), faithfully pattern important aspects of human disease (1, 2) including the breadth and organ specificity of distant dissemination and the engagement of gene-expression programs associated with patient outcome. Thus they have been widely employed in dissecting the molecular machinery used by metastatic cells to facilitate organ specific extravasion, co-option of beneficial local microenvironmental elements, evasion of deleterious signals, modification of the extracellular matrix, and others (1) (2) (3) . Despite these advances in our understanding of metastatic progression, the processes by which cancer cells acquire metastatic potential at late stages of disease remain poorly understood.
During the early stages of cancer, successive genetic alterations affecting key cell regulatory pathways propel cells from normal, to hyperplastic, and eventually to malignant states. Beyond the characteristics of malignancy, metastatic cells must procure the functions necessary to grow in hostile and unfamiliar microenvironments. A natural conclusion would be that the progression to metastatic competence must be driven by additional genetic mutations (4, 5) . Guided by this premise, several recent studies examined the genomes of patient-derived primary and metastatic tumor samples (6) (7) (8) (9) (10) . Though fruitful in characterizing population dynamics during disease progression and tumor heterogeneity, none of the studies found evidence for recurrent metastasis-specific driver mutations (3, 11) . Based on current research, the contribution of genetic mutations to the acquisition of specific metastatic traits by cancer cell populations remains unclear.
Here we interrogate the genetic evolution of metastatic phenotypes in our transplantable and phenotypically stable metastatic model systems. The use of such tumor models in genetic studies provides several advantages including the lack of normal tissue contamination, the reproducibility of phenotypes displayed by incumbent cell populations, and the ability to sample the bulk population. Previous studies have shown that xenograft models acquire few additional mutations while passaged in vitro or in vivo (6) . We sequenced the exomes of the above tumor and metastasis models and examined phylogenetic relationships as well as patterns of enrichment of genetic variations. In addition to providing an alternate platform with which to study the genetic evolution of metastatic competence, these efforts provide an important characterization of a platform widely used to study metastasis. We observed that stable metastatic cell populations could be selected in vivo with limited acquisition of additional genetic alterations. In addition, we found that the genetic selection of preexisting oncogenic mutations, was beneficial to metastatic competence in vivo.
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The FASTQ files were processed to remove any adapter sequences and low quality bases at the ends of the reads. The reads were mapped to the hg19 assembly using the BWA aligner.
We used Picard Tools' MarkDuplicates to remove duplicate reads. The alignment file was processed using the GATK toolkit. We performed a local realignment around indels and recalibrated the base quality scores of the aligned reads. We called variants with UnifiedGenotyper, and recalibrated the probability of each variant. The flag from UnifiedGenotyper had to not be equal to LowQual (phred-scaled Qscore < 30). Greater than 12x coverage was required for all sequence variations. For variants in metastatic derivatives the sample had to be covered such that the alternative allele was seen in 3 or more reads and the parental sample had to have 3 or more reads matching the reference sequence. The nonreference allele frequency (NRAF) of variants in metastatic derivatives had to be greater than 0.15. The difference in the NRAF of metastatic derivative samples and parental samples had to be greater than 0.25 for enriched or depleted variants. Whole exome sequencing data have been deposited in the Sequence Read Archive (SRA; BioProject accession: PRJNA282161). 
RESULTS

Whole exome sequencing and characterization of sequence variations
We performed comparative whole exome sequencing on five matched sets of phenotypically stable transplantable tumor and metastasis models that were derived from heterogeneous Table S1 ). Solution-based hybrid exome capture followed by massively parallel paired end sequencing produced an average coverage of greater than 105X in all samples (Supplementary Table S2 ) and accurately detected many of the mutations already reported for these cancer cell lines (Supplementary Table S3 ). The criteria for variant calling are 
Identification of copy number variations unique to metastatic cell populations
From our whole exome sequencing data we identified regions of copy number variations for each of our model systems ( Supplementary Fig. S2A ). Though we found segments of DNA that were differentially amplified or deleted in the metastatic derivates compared to their respective parental lines, correlation of these data to gene expression data showed that only a small fraction of the genes contained in these regions were differentially expressed (Supplementary Table S5 ). We also found one model system, PC9, in which no copy number variations produced differential gene expression changes between the parental and metastatic lines. Similar to the lack of commonality between sequence variations, we also did not find common regions of copy number variations across model systems.
Evidence for genetic selection in metastatic cell populations
To better understand the global patterns of genetic evolution associated with the development of strongly metastatic phenotypes we examined shifts in the frequency of variant alleles (18) between populations of metastatic and matched weakly-metastatic parental cells. We identified six categories of frequency shifts associated with the selection of metastatic cells (Fig. 1B) . The vast majority of sequence variations identified exists at similar allelic frequencies in metastatic and parental lines in each of the five tumor model systems (Category 1) (Fig. 1C-E) and includes clonal and subclonal sequence alterations in known cancer drivers as well as genes previously unassociated with disease (Supplementary Table S4 ). In the case of PC9 all sequence variations fall into this category as no sequence variations were detected that significantly differ between the parental and metastatic derivative lines. 
The metastatic derivatives of MDA-MB-231 cells include six independently isolated cell lines with tropisms to three different organs (Supplementary Table S1 ) (12) (13) (14) permitting comparisons of the genetic relatedness of metastases with varying or similar organotropisms.
Pairwise comparisons of the variant allele frequencies revealed large similarities in the genetic makeup of metastatic derivatives that target the same organs ( Supplementary Fig. S3A-C) .
However, the phenotypically similar cell populations are not isogenic and each derivative contains clusters of sequence variations at higher allelic frequencies than in the corresponding line.
To examine the structure of the evolutionary relationships between weakly metastatic MDA-MB-231 cells and their stably metastatic derivatives we constructed a phylogenetic tree utilizing differences in allele frequencies as a measure of genetic distance (Fig. 1F) . For comparison, the germline genotype is simulated with an assumption that the germline contains none of the sequence variations detected. The branched evolutionary pattern partially separates the metastatic lines by their tropism for different organ systems. Derivatives that target the lung appear to be more closely related to each other than to derivatives that target other organs.
However, the remaining metastatic lines do not segregate according to their tropism for target tissues nor do they diverge significantly from the parental line.
Selection of oncogenic mutations in metastatic cell populations
Though we did not find a general pattern of genetic evolution by which cells gain metastatic competence, it is possible that individual positively selected sequence alterations confer a growth or survival advantage in cancer cell populations. To uncover such variants, we searched for known cancer drivers (11, 19, 20) among the genes altered in the metastatic samples. We found sequence variations in 29 to 35 known cancer associated genes per sample. Many of these sequence variations have not been previously described and it is unnknown if they hold any functional consequence. Only a small fraction of these are significantly enriched or depleted in metastatic populations ( Fig. 2A, red bars, blue bars) . Similarly we found few cancerassociated genes among those for which there was a correlation between copy number alteration and significant changes in gene expression (Supplementary Table S5 ). However, we did not find any recurrent copy number variations for cancer-associated genes across the individual derivatives of the MDA-MB-231 system or across our model systems ( Supplementary   Fig. S4 ).
The well-characterized oncogenic mutations, KRAS G13D and BRAF G464V , are present but not rare in the MDA-MB-231 parental line (allelic frequencies: 0.54 and 0.56, Supplementary Table S4 ).
Sanger sequencing (Fig. 2B -C, top panels) validated the presence and pattern of enrichment for each of these variations in the metastatic derivatives ( Fig. 2B -C, bottom panels, Supplementary Table S4 ). To examine the nature of the selection for these two oncogenic alleles, we investigated copy number changes in chromosomes 7 and 12 ( Fig. 2D) . A deletion in chromosome 7 accounts for the loss of the wild-type allele of BRAF in the MDA-MB-231 metastatic derivatives (Fig. 2D, top panel) . In the case of KRAS
G13D
, the copy number patterns are more complex (Fig. 2D, bottom panel) . In the sub-triploid MDA-MB-231 cells, chromosome 12 is present at diploid levels in the parental line and thus maintains one copy of each allele at the KRAS locus (21) . The brain metastatic derivative shows no evidence for genetic loss, indicating that the selection for KRAS G13D in these cells is a result of copy-neutral loss of heterozygosity. The lung metastatic derivative displays a gain of at least one copy at the KRAS locus.
Selection for oncogenic mutations in metastatic cells promotes metastasis
Metastasis requires the ability to reinitiate tumor outgrowth after disseminated cells infiltrate tissue. Because KRAS or BRAF oncogenes drive basic tumorigenic functions we postulated that (23) (24) (25) . To test whether wild-type BRAF could also inhibit tumor initiation and growth, we performed in vivo metastasis and tumor initiation assays after reintroducing the wild-type allele of BRAF ( Supplementary Fig. S5A-C) into metastatic cells in which there was evidence for selection of oncogenic BRAF G464V . We injected these cells into the left ventricle of immunodeficient mice and quantitated metastatic growth by bioluminescence.
Reintroduction of wild-type BRAF led to a significant reduction in metastatic burden (Fig. 3A) .
We also injected a limiting dilution (100 cells) of cells subcutaneously into the flanks of mice and quantitated tumor formation over time. Reintroduction of the wild-type allele led to a decrease in the number and size of subcutaneous tumors ( Fig. 3B; Supplementary Fig. 5D ) suggesting that the wild-type allele of BRAF inhibits tumor initation and growth. 
DISCUSSION
Our results, obtained with experimental models systems that allow comparisons between cell populations with distinct metastatic activity, shed light on several general principles.
Amplification, through non-genetic measures, of oncogenic signals preexisting in primary cancers has been demonstrated to improve tumor-initiating fitness in metastatic cells in breast cancer (26) (27) (28) (29) . Indeed KRAS G12V has been shown to be amplified in a metastatic cancer clone in pancreatic cancer (7) . The present results provide genetic evidence for the same principle.
We found recurrent enrichment of the BRAF G464V allele in independently derived metastatic cell populations. We found in vivo that the selection for this oncogeneic allele at the expense of the wild-type allele confers a functional advantage to metastatic cell populations resulting in increased metastatic burden.
Genetic alterations can contribute to metastatic phenotypes, as we show in the MDA-MB-231
triple-negative breast carcinoma model and as the presence of KRAS or BRAF mutations have been associated with increased metastasis in colorectal cancer (30) (31) (32) . It may be possible that other sequence variations found to be enriched in metastatic populations if tested may prove advantageous to metastatic ability. However, we did not find the acquisition of genetic alterations to be essential in all other cases. Metastatic derivatives from the OS-RC-2 renal cell carcinoma and PC9 lung adenocarcinoma models, despite displaying a dramatically increase metastatic phenotype (15, 16) , displayed almost no enrichment for variants (private or preexisting) over matched parental lines. In addition the PC9 metastatic derivative contained no significant changes in copy number compared to its matched parental line. This result is not surprising given the estimate that each additional driver mutation only provides a small selective growth advantage of ~0.4% (33) . If the disparate phenotypes exhibited by the metastatic and parental cell populations in our model systems can be driven without the accumulation of additional genetic mutations, the acquisition of metastatic traits would likely conferred by Our data also suggests that modifications to existing oncogenic pathways that increase the representation of preexisting mutations within the cell population may enhance metastatic fitness. This, combined with non-genetic heritable alterations, may be sufficient for the increased probability that a cancer cell population will generate metastatic lesions. Results from aCGH data were compiled to show comparisons between metastatic derivatives and parental lines. 
